Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,209.01
(
1.02%
)
US TECH 100
26,709.60
(
0.00%
)
Dow Jones
49,652.14
(
1.62%
)
Brent Oil
110.81
(
0.41%
)
Bitcoin
77,089.98
(
1.00%
)
News Focus
News Focus
Post# of 257473
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122916
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biocqr post# 223637

Monday, 03/06/2023 12:05:49 PM

Monday, March 06, 2023 12:05:49 PM

Post# of 257473
ADAP acquires TCRR for $2.04*/sh in stock—a 69%* premium by my calculation:

https://finance.yahoo.com/news/adaptimmune-tcr2-therapeutics-announce-strategic-110000040.html

Despite the nominal premium, this deal is effectively a takeunder insofar as TCRR has had a deeply negative enterprise value for the past 18 months or so. Even after today’s bounce, TCRR is down about 90% from its 2019 IPO (#msg-146837794).

*Based on ADAP’s opining price of $1.35 today, TCRR’s closing price of $1.21on Friday, and the exchange ratio of 1.5117 shares of ADAP for each share of TCRR.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today